Case Reports in Oncological Medicine最新文献

{"title":"Isolated Cervical Seminoma Without Testicular or Mediastinal Primary: A Rare Extragonadal Germ Cell Tumor Presentation.","authors":"Nikita Jhangiani, Saivaroon Gajagowni, Joanna Song, Gloria Mensah, Sergio Villegas De Leon, Michael Glover, Son Viet Nguyen","doi":"10.1155/crom/5148074","DOIUrl":"10.1155/crom/5148074","url":null,"abstract":"<p><p>Germ cell tumors (GCTs) most commonly arise in the testes, with 1%-5% occurring at extragonadal sites, typically along the midline such as the mediastinum or retroperitoneum. We present a case of an exceptionally rare extragonadal seminoma confined to the cervical lymph nodes. Given the atypical location, diagnosis was difficult and required multiple biopsies to ensure appropriate correlation with histologic, immunophenotypic, and cytogenetic findings. Detection of 12p gain by FISH was pivotal in confirming germ cell origin. This case emphasizes the importance of maintaining a broad differential for atypical lymphadenopathy and will review the diagnostic challenge provided by this presentation.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"5148074"},"PeriodicalIF":0.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Resection With Hyperthermic Intrathoracic Perfusion Chemotherapy for Thymoma Recurrence.","authors":"Paula Duarte D Ambrosio, Gustavo Schvartsman, Mathias de Souza Ribeiro, Enzo Campedelli Borges, Marina Cardoso de Castro, Paulo Manuel Pêgo Fernandes, Ricardo Mingarini Terra","doi":"10.1155/crom/1802396","DOIUrl":"10.1155/crom/1802396","url":null,"abstract":"<p><p>Thymoma recurrence with pleural dissemination remains a therapeutic challenge, often requiring multimodal treatment strategies. Cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (HITHOC) has emerged as a promising approach for selected patients; however, reports using minimally invasive robotic platforms are limited. We present the case of a 41-year-old woman with pleural and lymph node recurrence of type AB thymoma 3 years after robotic extended thymectomy. The patient underwent robotic-assisted cytoreductive surgery, including complete parietal pleurectomy and resection of pleural, pericardial, and subaortic lymph node lesions, followed by HITHOC with cisplatin and doxorubicin. The procedure was performed safely, with no major perioperative complications. The patient was discharged after 7 days and remained disease-free at 2-year follow-up. This case highlights the feasibility, safety, and potential oncological benefits of combining robotic cytoreductive surgery with HITHOC in the management of recurrent thymoma with pleural involvement. This minimally invasive multimodal strategy may represent a valuable option for carefully selected patients, although further studies with larger cohorts and longer follow-up are warranted.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"1802396"},"PeriodicalIF":0.6,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic Fever in a Patient With Cervical Carcinoma: A Diagnostic Challenge and Management Approach.","authors":"Ingrid Masilenge, Lucylight Mallya, Ravinder Jandwa, Samwel Mallango, Queen Tarimo, Kezia Tessua, Alita Mrema","doi":"10.1155/crom/6473606","DOIUrl":"10.1155/crom/6473606","url":null,"abstract":"<p><strong>Introduction: </strong>Persistent fever in patients with cancer presents a significant diagnostic challenge, particularly in settings where infectious diseases are highly prevalent. Neoplastic fever is an important noninfectious cause of fever that may mimic infection and result in unnecessary investigations, antimicrobial therapy, and delays in cancer treatment.</p><p><strong>Case presentation: </strong>We report a case of a 45-year-old female patient with advanced cervical carcinoma who presented with persistent high-grade fever unresponsive to antibiotics. An extensive infectious workup was negative. Following exclusion of alternative causes, a naproxen challenge was performed, resulting in rapid resolution of fever within 24 h. Fever recurred upon withdrawal and resolved again after naproxen reintroduction, supporting the diagnosis of neoplastic fever.</p><p><strong>Conclusion: </strong>Neoplastic fever should be considered early in cancer patients with persistent unexplained fever, particularly in tuberculosis- and malaria-endemic settings. Following exclusion of infection, the naproxen challenge may provide a simple and affordable diagnostic step to distinguish neoplastic fever from infectious causes, reduce unnecessary antimicrobial use, shorten diagnostic delays, and facilitate timely cancer-directed therapy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"6473606"},"PeriodicalIF":0.6,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenalidomide-Associated Rhabdomyolysis Progressing to Bilateral Compartment Syndrome and Permanent Foot Drop.","authors":"Karthik Iyer, Sanjna Chetan, Anoohya Arkala, Craig S Siegel, Bhaskara Gadi, Cristian Popu, Vikram Oke, Briccio S Cadiz","doi":"10.1155/crom/6693120","DOIUrl":"10.1155/crom/6693120","url":null,"abstract":"<p><p>Lenalidomide is widely used for the treatment and maintenance of multiple myeloma and is generally considered to have a favorable safety profile. However, severe skeletal muscle toxicity associated with lenalidomide has been rarely reported. We describe a 52-year-old man with multiple myeloma who developed acute bilateral lower-extremity pain, cramping, weakness, and paresthesia while receiving lenalidomide therapy. Laboratory evaluation revealed marked rhabdomyolysis, and imaging and clinical findings were consistent with bilateral lower-leg compartment syndrome. Despite emergent bilateral fasciotomies resulting in resolution of pain and normalization of creatine kinase levels, the patient developed persistent bilateral foot drop with residual sensory deficits. To our knowledge, this represents the first reported case of lenalidomide-associated rhabdomyolysis progressing to bilateral compartment syndrome with permanent neurologic sequelae. This case underscores the importance of early recognition of muscle toxicity, prompt laboratory evaluation, and timely surgical intervention to mitigate irreversible functional impairment.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"6693120"},"PeriodicalIF":0.6,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Small Cell Neuroendocrine Carcinoma of the Prostate: A Rare and Aggressive Case Report From Bangladesh.","authors":"Md Arifur Rahman, Zinia Jannat Ananna, Mostofa Arafat Islam, Hasin Mesbah Bin Siddique, Mashud Parvez, Sayem Hossain","doi":"10.1155/crom/2821229","DOIUrl":"10.1155/crom/2821229","url":null,"abstract":"<p><strong>Background: </strong>Small cell neuroendocrine carcinoma of the prostate (SCNEC) is a rare but devastatingly aggressive malignancy, carrying a median survival well under 13 months even with multimodal treatment. It may arise de novo or emerge as a treatment-resistance phenotype following androgen deprivation in conventional prostatic adenocarcinoma. A defining and clinically treacherous feature is its failure to elevate serum PSA in proportion to tumour burden-a phenomenon termed the 'PSA paradox'-which routinely delays diagnosis, particularly in resource-limited settings.</p><p><strong>Case presentation: </strong>We report a 35-year-old Bangladeshi man who presented with obstructive urinary symptoms, constipation and deep pelvic pain. His serum PSA was only 0.77 ng/mL despite a 6.5 × 6.0 × 5.5 cm prostate mass with liver metastases, extensive osteoblastic bone deposits (SUVmax ~18 on 18F-FDG PET/CT), left hydronephrosis and regional lymphadenopathy. Initial TRUS-guided biopsy was reported as Gleason 5 + 5 = 10 adenocarcinoma. Given the PSA-disease burden mismatch, biopsy slides were immediately re-evaluated; haematuria and acute urinary retention necessitated urgent TURP on 4 December 2024, which confirmed a pure de novo SCNEC with diffuse synaptophysin positivity and a Ki-67 index exceeding 60%. GATA3 and p40 were negative. Renal function was confirmed adequate before platinum therapy following palliative TURP(serum creatinine 1.2 mg/dL); etoposide-cisplatin (EP) chemotherapy was administered for six cycles with standard hydration, achieving a marked metabolic response on interim PET/CT. Consolidative pelvic IMRT (55 Gy/20 fractions) followed. Despite this approach, the disease relapsed within 3 months; second-line docetaxel produced no meaningful response. The patient died approximately 11 months from diagnosis.</p><p><strong>Conclusions: </strong>This case underscores the critical importance of recognising the PSA paradox in younger patients with bulky pelvic disease, the indispensable role of a comprehensive IHC panel in confirming the neuroendocrine phenotype and the urgent need for novel therapeutic strategies in this near-universally lethal malignancy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"2821229"},"PeriodicalIF":0.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13542580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Treatment of Docetaxel Liposomes and Sonodynamic Therapy With Verteporfin Liposomes in Patients With Cancer: A Report of Three Cases.","authors":"Yasuo Komura, Shintarou Kimura, Yumi Hirasawa, Ryo Takasaki, Saki Fukuro, Nguyen Thi Mai Thi, Miyaji Gengou, Lee Sang Woo, Osamu Imataki, Toru Yanagawa, Koichiro Homma","doi":"10.1155/crom/7515689","DOIUrl":"10.1155/crom/7515689","url":null,"abstract":"<p><p>Despite advances in medical technology, cancer treatment remains challenging. Our research focused on combining microtubule polymerization inhibitors with sonodynamic therapy (SDT) as a promising approach for cancer. SDT is a minimally invasive modality that uses tumor-selective sonosensitizers to induce the death of malignant and tumor-associated cells within the tumor microenvironment through targeted ultrasound irradiation. In this study, verteporfin was selected because of its dual properties of high ultrasound sensitivity and the ability to inhibit the yes-associated protein. Liposome-encapsulated docetaxel and verteporfin were employed to enhance tumor accumulation. This intervention demonstrated remarkable antitumor efficacy in three patients with ovarian metastases from gastric cancer, advanced gastric cancer, and lung metastases from breast cancer, respectively, without notable adverse events. Although the patients with ovarian and lung metastases had experienced progressive disease despite prior chemotherapy and immune checkpoint inhibitor treatment, our intervention successfully inhibited tumor progression. Furthermore, although conventional treatment options were considered unsuitable because of advanced age in the patient with gastric cancer, this intervention demonstrated a favorable safety profile and potential therapeutic benefit. To our knowledge, this study represents the first clinical report demonstrating the potential antitumor efficacy and safety of the combination of verteporfin liposomes, liposomal docetaxel, and SDT.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"7515689"},"PeriodicalIF":0.6,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving Complete Cytoreduction After Systemic Therapy for Stage IV Renal Carcinoma With Multicompartment Recurrence and Peritoneal Carcinomatosis: A Case Report.","authors":"Juan Pablo Usubillaga, Rodolfo Varela, Yeison Reina, Diana Carolina Franco, Juan Sebastián Valderrama, Martín Zapata-Laguado, Daniel Suso-Palau","doi":"10.1155/crom/9036511","DOIUrl":"10.1155/crom/9036511","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC) most commonly metastasizes to the lungs, bones, liver, and brain, whereas peritoneal involvement is exceedingly rare and typically associated with aggressive disease and poor prognosis. Although the combination of immune checkpoint inhibitors and tyrosine kinase inhibitors has significantly improved outcomes in metastatic ccRCC, reports documenting substantial pathological responses following these regimens remain limited. We describe the case of a 31-year-old male initially diagnosed with localized ccRCC (pT3aN0M0) after presenting with spontaneous retroperitoneal hemorrhage and undergoing radical nephrectomy. Seven months later, he developed progressive ascites and was restaged with extensive multicompartment recurrence, including peritoneal metastases, hepatic lesions, retroperitoneal lymphadenopathy, and tumor thrombus in the infrahepatic inferior vena cava. The patient was classified as poor risk according to the International Metastatic RCC Database Consortium criteria. Systemic therapy with pembrolizumab and lenvatinib was initiated, resulting in greater than 50% radiologic tumor reduction and marked clinical improvement after 14 cycles. Following this favorable response, complete cytoreductive surgery targeting all affected compartments was performed. Histopathological examination revealed extensive tumor necrosis with less than 1% residual viable tumor, confined to a single hepatic segment. The patient remains asymptomatic under close surveillance. To our knowledge, this is the first reported case of ccRCC with multicompartment metastatic disease involving peritoneal carcinomatosis treated with pembrolizumab plus lenvatinib followed by complete cytoreductive surgery, achieving near-complete pathological response, highlighting the potential of multimodal strategies in selected patients with advanced disease.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"9036511"},"PeriodicalIF":0.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Multicentric Breast Cancer With Opposite Molecular Phenotypes: A Case Report and Therapeutic Considerations.","authors":"Nelson Buelvas, Zully Acevedo","doi":"10.1155/crom/5068002","DOIUrl":"10.1155/crom/5068002","url":null,"abstract":"<p><strong>Background: </strong>Multifocal and multicentric breast cancers are increasingly diagnosed due to advances in imaging. Although some degree of molecular heterogeneity between tumor foci is recognized, most multicentric tumors share similar biological profiles. The presence of synchronous multicentric breast cancer with completely opposing molecular phenotypes remains exceptional.</p><p><strong>Case presentation: </strong>We report the case of a 67-year-old woman diagnosed with synchronous multicentric breast cancer of the left breast. One tumor focus showed a HER2-enriched phenotype (ER-negative, PR-negative, HER2-amplified, and Ki67 60%), whereas a second spatially distinct focus (both confirmed on the surgical specimen) exhibited a luminal A phenotype (ER 100%, PR 1%, HER2-negative, and Ki67 15%). Both lesions were confirmed by magnetic resonance imaging and independently biopsied. The patient underwent modified radical mastectomy and received adjuvant anti-HER2 targeted therapy and endocrine therapy. At 22 months of follow-up, she remains disease-free.</p><p><strong>Conclusion: </strong>This case highlights the importance of comprehensive imaging assessment and independent molecular characterization of all suspicious tumor foci in multicentric breast cancer, as molecular discordance may have significant prognostic and therapeutic implications.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"5068002"},"PeriodicalIF":0.6,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.","authors":"Anas Saad, Fahad Mohammad Daraan, Ibrahim Barghouth, Mouhammed Sleiay","doi":"10.1155/crom/7517129","DOIUrl":"10.1155/crom/7517129","url":null,"abstract":"<p><p>High-grade non-muscle-invasive bladder cancer (NMIBC) with lymphovascular invasion is rare in young adults. We report a 27-year-old male, a heavy hookah smoker, who presented with painless gross hematuria. Cystoscopy revealed a large papillary bladder tumor. Transurethral resection demonstrated high-grade pT1 urothelial carcinoma with lymphovascular invasion and uninvolved muscularis propria. Repeat resection 4 weeks later confirmed no residual malignancy. The patient received six induction doses of intravesical BCG and remains recurrence-free at follow-up. This case illustrates an uncommon presentation of high-risk NMIBC in a young patient and demonstrates an excellent early response to bladder-preserving therapy despite adverse pathological features.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"7517129"},"PeriodicalIF":0.6,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-Mediated Hepatotoxicity Associated With Ribociclib: A Multipatient Case Series and Management Strategy.","authors":"Jemma Buchalter, Helen O Donovan, Emmet Jordan, Zita Galvin, Janice M Walshe","doi":"10.1155/crom/2417755","DOIUrl":"10.1155/crom/2417755","url":null,"abstract":"<p><p>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), when combined with endocrine therapy, have significantly transformed the management of hormone receptor-positive, HER2-negative metastatic breast cancer. Ribociclib, abemaciclib and palbociclib improve progression-free survival and delay chemotherapy initiation, with ribociclib additionally demonstrating an overall survival advantage. The NATALEE trial has further expanded the role of CDK4/6 inhibition in early breast cancer, showing significant improvement in 4-year invasive disease-free survival with adjuvant ribociclib in HR+/HER2-negative disease. Despite their shared mechanisms of targeting the CDK4/6-p16-retinoblastoma pathway, these agents differ in pharmacokinetics, kinase selectivity and toxicity. Hepatoxicity is a recognised adverse event of ribociclib with all grade toxicity occurring in around 20% of patients and Grade 3-4 events in 11%-15%. This drug-induced liver injury (DILI) typically resolves with drug withdrawal.Immune-mediated or autoimmune-like presentations of ribociclib-associated hepatotoxicity have been reported, although detailed management strategies remain poorly described. We report a series of five patients who developed ribociclib-induced liver injury that failed to improve with cessation of therapy, and instead demonstrated features suggestive of an immune-mediated mechanism. Hepatotoxicity occurred predominantly within the first few treatment cycles, highlighting the importance of early monitoring. All patients experienced significant biochemical improvement with corticosteroids; however, three developed recurrent transaminase elevation during tapering. Two required tacrolimus as a steroid-sparing agent, allowing eventual withdrawal of immunosuppression without relapse. Rechallenge with ribociclib in one patient led to recurrent hepatotoxicity, again responsive to steroids. Three patients were subsequently treated with palbociclib without recurrence of hepatotoxicity, maintaining disease control for more than 2 years. Liver biopsy in four patients was consistent with DILI in three and revealed mixed DILI with underlying primary biliary cholangitis in one, illustrating the complexity of managing hepatotoxicity in individuals with comorbid liver disease. This series highlights a pattern suggestive of immune-mediated ribociclib-induced hepatotoxicity responsive to short course corticosteroids with or without additional immunosuppression. Palbociclib appears to be a safe alternative, enabling continuation of CDK4/6-targeted therapy without premature transition to chemotherapy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2026 ","pages":"2417755"},"PeriodicalIF":0.6,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13430969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}